A randomized double blind placebo controlled trial of controlled release Mebeverine in Irritable Bowel Syndrome

Department of Pharmacology0 个研究点目标入组 40 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•1)Patients having recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months.
•2)Patients having loose or watery stool more than three per day.

•Female patients who are pregnant or breast-feeding.
•Patients having infrequent bowel movements(less than 3 per week)
•Patients having hard or lumpy stools
•Patients strain during defaecation
•Patients who have been treated with mebeverine within 4 weeks prior to study
•Patients with history of hypersensitivity to Mebeverine.
•Patients suffering from debilitating chronic diseases including frankly uncontrolled diabetes and advanced malignancy.
•Patients suffering from frankly immunocompromising disorders such as HIV/AIDS.
•Patients on systemic antimicrobials, corticosteroids or any other medication known to influence disease symptoms currently or within last 4 weeks.
•Patients suffering from alcoholism, substance abuse or psychiatric disorders that are liable to make them unreliable trial subjects.
•Patients without adequate caregiver support at home who can supervise daily oral administration as well as any adverse side effects. Any other condition which, in the opinion of the investigators, is likely to substantially increase the risk of non- adherence or the possibility of confounding of results.

发起方